NCT05168787Completed
Efficacy and Safety of Sacubitril/Valsartan in African American Patients With Heart Failure With Reduced Ejection Fraction
Source: ClinicalTrials.gov · Last updated 27 Mar 2026
Brief summary (registry, in English)
There is limited long-term evidence specific to AAs with HFrEF on sacubitril/valsartan therapy. Plasma NT-proBNP levels are lower in AA individuals as compared to Caucasian individuals in general. However, the mechanism of action of sacubitril specifically targets the activity of BNP. Therefore, there is the potential that the mechanism of action of sacubitril/valsartan may be less effective in AAs.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 6558 (actual)
- First submitted
- 9 Dec 2021
- Start date
- Aug 2020
- Primary completion date
- Jul 2025
- Lead sponsor
- Methodist Health System
- Diseases
- Heart failure
- NCT number
- NCT05168787
What you commit to
- Study type: Observational
- Participants enrolled: 6558
- From Aug 2020 to the primary completion date, Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients not meeting inclusion criteria
Who the study is looking for
- Self-identified as AA
- NYHA class II-IV symptoms
- Left ventricle EF \<40%
- Receiving stable doses of standard therapy, including ACE inhibitors or ARBs, ARNI (within a month from discharge), combination H-ISDN, beta blockers, digoxin, spironolactone, and diuretics as tolerated.
- Patient must have minimum of three months follow-up
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Methodist Dallas Medical Center Pharmacy Coordinator of this site? Confirm its status | Dallas | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.